Design Therapeutics (DSGN) Share-based Compensation (2020 - 2026)
Design Therapeutics recorded quarterly Share-based Compensation of $3.9 million in Q1 2026, up 14.24% quarter-over-quarter from $3.4 million in Q4 2025, and up 10.88% year-over-year from $3.5 million in Q1 2025.
Design Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 10.88% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $14.9 million (up 11.22% YoY), while the FY2025 annual figure was $14.5 million, up 11.3% from the prior year.
- Share-based Compensation came in at $3.9 million for Q1 2026 at Design Therapeutics, up from $3.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q2 2025 to a low of $2.4 million in Q1 2022.
- A 5-year average of $3.3 million and a median of $3.3 million in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation surged 264.76% in 2022 and fell 11.44% in 2023, its largest moves.
- Design Therapeutics' Share-based Compensation stood at $3.1 million in 2022, then slipped by 11.44% to $2.7 million in 2023, then advanced by 27.42% to $3.5 million in 2024, then fell by 1.04% to $3.4 million in 2025, then climbed by 14.24% to $3.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.9 million, $3.4 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | 3.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.92 Mn |
| Mar 31, 2026 | 3.92 Mn |
| Dec 31, 2025 | 3.44 Mn |
| Dec 31, 2025 | 3.44 Mn |
| Sep 30, 2025 | 3.59 Mn |
| Sep 30, 2025 | 3.59 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Mar 31, 2025 | 3.54 Mn |
| Dec 31, 2024 | 3.47 Mn |
| Dec 31, 2024 | 3.47 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 3.30 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 2.72 Mn |
| Dec 31, 2023 | 2.72 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Mar 31, 2023 | 3.43 Mn |
| Mar 31, 2023 | 3.43 Mn |
| Dec 31, 2022 | 3.08 Mn |
| Dec 31, 2022 | 3.08 Mn |
| Sep 30, 2022 | 2.87 Mn |
| Sep 30, 2022 | 2.87 Mn |
| Jun 30, 2022 | 2.62 Mn |
| Jun 30, 2022 | 2.62 Mn |
| Mar 31, 2022 | 2.36 Mn |
| Mar 31, 2022 | 2.36 Mn |
| Dec 31, 2021 | 1.56 Mn |
| Dec 31, 2021 | 1.56 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 1.24 Mn |
| Mar 31, 2021 | 647,000.00 |
| Mar 31, 2021 | 647,000.00 |
| Dec 31, 2020 | 421,000.00 |
| Dec 31, 2020 | 421,000.00 |
| Sep 30, 2020 | 15,000.00 |
| Sep 30, 2020 | 15,000.00 |
| Jun 30, 2020 | 10,000.00 |
| Jun 30, 2020 | 10,000.00 |
| Mar 31, 2020 | 4,000.00 |
| Mar 31, 2020 | 4,000.00 |